信达生物IBI363再获FDA快速通道资格认定;金斯瑞2024年净利润同比重大增长

Ofweek光电信息网
18 Feb

信达生物出海又有收获。2月17日,信达生物宣布,PD-1/IL-2α-bias双特异性抗体融合蛋白IBI363获得FDA授予快速通道资格,拟定适应症为抗PD-(L)1免疫检查点抑制剂及含铂化疗治疗后进展的局部晚期或转移性鳞状非小细胞肺癌。金斯瑞生物2024年业绩似乎不错。2月16日,金斯瑞生物科技公告称,集团预期2024年的净利润较2023年有重大增长。不过,在公告中,公司并未公布具体增幅数字。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10